Differential agonist and inverse agonist profile of antipsychotics at D2L receptors coupled to GIRK potassium channels

Neuropharmacology

Volumn 52, Issue 4, 2007, Pages 1106-1113

  Heusler, Peter ^a   Newman Tancredi, Adrian ^a   Castro Fernandez, Annabelle ^a   Cussac, Didier ^a  

^a INSTITUT DE RECHERCHE PIERRE FABRE   (France)

Author keywords

Antipsychotic; Dopamine D2L receptor; G protein coupled inward rectifier potassium channels; Inverse agonist; Partial agonist; Xenopus oocytes

Indexed keywords

(3 EXO) 8 BENZOYL N [(7 CHLORO 2,3 DIHYDRO 1,4 BENZODIOXIN 1 YL)METHYL] 8 AZABICYCLO 3.2.1]OCTANE 3 METHANAMINE; 2 [(2,2 DIMETHYL 2 ,3 DIHYDROBENZOFURAN 7 YLOXY)ETHYL](3 CYCLOPENTEN 1 YL BENZYL)AMINE; 2 DIPROPYLAMINO 5 METHOXY 1 METHYLTETRALIN; 3 [4 (4 CHLOROPHENYL) 4 HYDROXYPIPERIDIN LEVO YL]METHYL 1H INDOLE; 5 [4 [5 (4 FLUOROPHENYL) 3 PYRIDINYLMETHYL] 1 PIPERAZINYL] 1,4 BENZODIOXAN; APOMORPHINE; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BIFEPRUNOX; CLOZAPINE; COMPLEMENTARY RNA; DOPAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR STIMULATING AGENT; EMONAPRIDE; F 15063; G PROTEIN COUPLED INWARDLY RECTIFYING POTASSIUM CHANNEL; HALOPERIDOL; L 741626; NEUROLEPTIC AGENT; PARTIAL AGONIST; PRECLAMOL; QUINPIROLE; RACLOPRIDE; SARIZOTAN; SEROTONIN 1A RECEPTOR; SSR 181507; UNCLASSIFIED DRUG; ZIPRASIDONE;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; GENE EXPRESSION SYSTEM; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; WILD TYPE; XENOPUS LAEVIS;

ANIMALS; ANTIPSYCHOTIC AGENTS; DOPAMINE AGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; G PROTEIN-COUPLED INWARDLY-RECTIFYING POTASSIUM CHANNELS; HUMANS; MEMBRANE POTENTIALS; MICROINJECTIONS; OOCYTES; PATCH-CLAMP TECHNIQUES; RECEPTORS, DOPAMINE D2; SEROTONIN AGONISTS; XENOPUS LAEVIS;

EID: 33847281318     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2006.11.008     Document Type: Article

References (47)

1. Akam E., and Strange P.G. Inverse agonist properties of atypical antipsychotic drugs. Biochem. Pharmacol. 67 (2004) 2039-2045
2. 1Aagonist properties. Neuropsychopharmacology 31 (2006) 1869-1879
3. 2S receptors coupled to extracellular signal-regulated kinase. Eur. J. Pharmacol. 534 (2006) 63-70
4. 2 receptors. J. Pharmacol. Exp. Ther. 302 (2002) 381-389
5. 3 partial agonist. J. Pharmacol. Exp. Ther. 315 (2005) 1278-1287
6. 1A receptor agonist. I: neurochemical and electrophysiological profile. Neuropsychopharmacology 28 (2003) 2064-2076
7. 2 dopamine receptor/G protein interaction. Evidence for agonist selection of G protein subtype. J. Biol. Chem. 276 (2001) 28667-28675
8. 2 receptors: G protein activation and prolactin release. Eur. J. Pharmacol. 535 (2006) 135-144
9. 4 receptors: comparison with typical and atypical antipsychotics. Soc. Neurosci. Abstr. (2006) 332.4
10. 4 partial agonist properties: II. Behavioural profile in models of positive, negative symptoms and cognitive deficits of schizophrenia. Int. J. Neuropsychopharmacol. 9 Suppl. 1 (2006) P 01.165
11. Farah A. Atypicality of atypical antipsychotics. Prim. Care Companion: J. Clin. Psychiatry 7 (2005) 268-274
12. 2L cell line: evidence for induction of ligand-specific receptor states. Mol. Pharmacol. 66 (2004) 97-105
13. o G proteins: evidence for agonist regulation of G protein selectivity. Br. J. Pharmacol. 138 (2003) 775-786
14. αo fusion protein expressed in Sf9 cells. FEBS Lett. 545 (2003) 155-160
15. Gregerson K.A., Flagg T.P., O'Neill T.J., Anderson M., Lauring O., Horel J.S., and Welling P.A. Identification of G protein-coupled, inward rectifier potassium channel gene products from the rat anterior pituitary gland. Endocrinology 142 (2001) 2820-2832
16. 2 dopamine receptors. Br. J. Pharmacol. 121 (1997) 731-736
17. 1A receptors in Xenopus oocytes: evidence for agonist-directed trafficking of receptor signalling. Neuropharmacology 49 (2005) 963-976
18. 2 receptor signalling. Soc. Neurosci. Abstr. 913 (2005) 2
19. 1A receptor. Eur. J. Pharmacol. 441 (2002) 137-140
20. Kapur S., and Remington G. Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia. Annu. Rev. Med. 52 (2001) 503-517
21. 2 receptors. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 27 (2003) 1081-1090
22. Kenakin T. Efficacy as a vector: the relative prevalence and paucity of inverse agonism. Mol. Pharmacol. 65 (2004) 2-11
23. Kovoor A., Celver J.P., Wu A., and Chavkin C. Agonist induced homologous desensitization of μ-opioid receptors mediated by G protein-coupled receptor kinases is dependent on agonist efficacy. Mol. Pharmacol. 54 (1998) 704-711
24. Koyrakh L., Lujan R., Colon J., Karschin C., Kurachi Y., Karschin A., and Wickman K. Molecular and cellular diversity of neuronal G-protein-gated potassium channels. J. Neurosci. 25 (2005) 11468-11478
25. Lawler C.P., Prioleau C., Lewis M.M., Mak C., Jiang D., Schetz J.A., Gonzalez A.M., Sibley D.R., and Mailman R.B. Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology 20 (1999) 612-627
26. Levine N., Ethier N., Oak J.N., Pei L., Liu F., Trieu P., Rebois R.V., Bouvier M., Hebert T.E., and Van Tol H.H. G protein-coupled receptors form stable complexes with inwardly rectifying potassium channels and adenylyl cyclase. J. Biol. Chem. 277 (2002) 46010-46019
27. + channel proteins GIRK1 and GIRK2 and their altered expression in weaver brain. J. Neurosci. 16 (1996) 7137-7150
28. + channel determined by construction of multimeric cDNAs. Neuron 9 (1992) 861-871
29. 1Areceptor agonist potential antipsychotic drug. Neuropsychopharmacology 32 (2007) 78-94
30. Meltzer H.Y., Li Z., Kaneda Y., and Ichikawa J. Serotonin receptors: their key role in drugs to treat schizophrenia. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 27 (2003) 1159-1172
31. 1A receptors. J. Pharmacol. Exp. Ther. 295 (2000) 853-861
32. Neve K.A., Seamans J.K., and Trantham-Davidson H. Dopamine receptor signaling. J. Recept. Signal Transduct. Res. 24 (2004) 165-205
33. 1A receptors: affinity, efficacy and potential implications for treatment of schizophrenia. Int. J. Neuropsychopharmacol. 8 (2005) 341-356
34. 4 partial agonist properties: I. In vitro, neurochemical and neuroendocrine profiles. Int. J. Neuropsychopharmacol. 9 Suppl. 1 (2006) P 01.164
35. 2 dopamine receptors. Neuropharmacology 47 (2004) 860-872
36. + channel, GIRK. Neuron 33 (2002) 87-99
37. 1A ligands in preclinical behavioral models for antipsychotic and extrapyramidal effects. Psychopharmacology (Berl.) 144 (1999) 20-29
38. Remington G. Understanding antipsychotic "atypicality": a clinical and pharmacological moving target. J. Psychiatry Neurosci. 28 (2003) 275-284
39. Shapiro D.A., Renock S., Arrington E., Chiodo L.A., Liu L.X., Sibley D.R., Roth B.L., and Mailman R. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 28 (2003) 1400-1411
40. 2S receptors render it a unique antipsychotic. Eur. J. Pharmacol. 515 (2005) 10-19
41. 2receptor-mediated signaling pathways. Neuropsychopharmacology 32 (2007) 67-77
42. Van Vliet B.J., Mos J., Van der Heijden J.A.M., Feenstra R., Kruse C.G., and Long S.K. DU 12790: a highly potent, atypical dopamine receptor ligand - a putative potent full spectrum antipsychotic with low EPS potential. Eur. Neuropsychopharmacol. 10 Suppl. 3 (2000) S293
43. z eliminates catalytic (collision) coupling. J. Biol. Chem. 275 (2000) 4166-4170
44. 4 dopamine receptors couple to G protein-regulated potassium channels in Xenopus oocytes. Mol. Pharmacol. 49 (1996) 656-661
45. 2S dopamine receptor: evidence for multiple, agonist-specific active conformations. Mol. Pharmacol. 54 (1998) 435-444
46. 2 dopamine receptor that adopts the activated conformation. J. Neurochem. 77 (2001) 493-504
47. 1B receptor to the phospholipase C pathway: inverse agonism to silent antagonism by neuroleptic drugs. J. Pharmacol. Exp. Ther. 304 (2003) 380-390